AXAxinet
Menu
Finance

Live market screen

Commercial Space Company Risk / Opportunity Ranking

Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.

Updated June 27, 2026

Companies analyzed
438
Ranked rows
876
Evidence links
356
Rows per page
20

Opportunity view

Showing rows 261-280 of 438; 20 rows per page.

Sorted by raw opportunity score
RankCompanyScoreThesis / Evidence
261
Agnikul Cosmos
lowweak
Opp 1
Risk 1

Thesis: Insufficient admissible reviewed sources evidence to form a positive thesis within the selected recent evidence window. Membership rationale says the company is a rocket startup raising funding and planning an orbital debut, but no surviving article/evidence are provided for direct support.

Why now: Why now is unsupported because the reviewed sources show zero evidence after recent evidence filtering despite many articles considered; recency-specific business state cannot be established from the provided evidence.

Caveats: Coverage debug shows zero evidence after recent evidence filtering. Membership rationale cannot substitute for cited directional evidence under the output rules. Absence of evidence is not positive or negative proof.

262
Airbus SE
lowweak
Opp 1
Risk 1

Thesis: The reviewed sources gives only weak context that Airbus was listed in a satellite-servicing landscape, which is insufficient on its own to support a strong positive thesis for a 1 year+ horizon.

Why now: There is no within the recent evidence window evidence available for Airbus; the only cited article is older context published March 4, 2025, outside the 90-day cutoff noted by the reviewed sources, so recency support is weak.

Caveats: Coverage after recent evidence window is effectively empty: articles after recent evidence window is 0. The available Airbus article is contextual and outside the 90-day recent evidence window. Cohort membership does not establish attractiveness.

263
Alta Ares
lowweak
Opp 1
Risk 1

Thesis: No positive thesis is supportable because the retained reviewed sources contain no direct positive evidence after recent evidence window.

Why now: Why now is weak: the reviewed sources show no retained evidence after recent evidence window, and the membership rationale says Alta Ares appears only in a broad funding roundup without enough company-specific detail.

Caveats: Phase-2 membership rationale references: but no article summary or direct retained evidence is available here for factual use. The reviewed sources itself says company-specific detail is insufficient.

264
Altamira Technologies Corporation
lowweak
Opp 1
Risk 1

Thesis: No positive thesis is supportable because the reviewed sources does not provide direct positive evidence or article summaries for Altamira in the scoring section.

Why now: The phase2 rationale notes only that Parsons acquired Altamira and references defense/national security themes, but no citable evidence are provided here. Coverage data shows zero articles after recent evidence window and zero evidence available.

Caveats: Ownership/acquisition context alone is not enough without direct evidence detail. No dated catalyst evidence is surfaced in the reviewed sources.

265
Amazon.com Inc.
lowweak
Opp 1
Risk 1

Thesis: The membership rationale references satellite and direct-to-device ambitions, but the reviewed sources contain no within the recent evidence window evidence or representative article summaries to support a current space-related opportunity thesis here.

Why now: No current catalyst can be established from the available evidence because post-recent evidence window evidence are absent.

Caveats: Extremely large mention universe is not conviction. No usable evidence were available after recent evidence window.

266
AnduraX
lowweak
Opp 1
Risk 1

Thesis: The reviewed sources' membership rationale says AnduraX is developing a reusable spaceplane and has VC backing, but no retained within the recent evidence window article evidence is available here to support an opportunity thesis.

Why now: There is no retained article or evidence row after the 90-day recent evidence window, so the reviewed sources does not establish a current catalyst or updated business state.

Caveats: Coverage is effectively empty after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Membership rationale references article IDs, and: but no or retained summaries are provided here. Scores remain low because positive or negative direction cannot be grounded with citable retained evidence.

267
Angkasa-X Holdings Corp.
lowweak
Opp 1
Risk 1

Thesis: No retained within the recent evidence window direct positive evidence is provided in the reviewed sources, so there is not enough support for a positive 1 year+ thesis.

Why now: There is no usable within the recent evidence window article evidence available for ranking; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window, so recency-sensitive judgment is not possible from these reviewed sources alone.

Caveats: Reviewed evidence notes one considered article for membership support but zero article IDs after recent evidence window and zero available evidence after recent evidence window, so ranking is constrained by evidence absence rather than business absence. Membership rationale references article: but the reviewed sources does not provide the article or a retained within the recent evidence window evidence row for ranking use.

268
Applied Aerospace & Defense Inc.
lowweak
Opp 1
Risk 1

Thesis: There is insufficient company-specific positive evidence in the reviewed sources to support an opportunity thesis. The only cited context is that the company was referenced as competition in a space-sector article and that the reviewed sources notes a $650M IPO, but no direct business traction, contract, product, or financial evidence within the recent evidence window is available (: unavailable in reviewed sources).

Why now: Why now is weak because the reviewed sources show zero evidence available after the 90-day recent evidence window cutoff date of March 29, 2026, so recency-based catalysts cannot be established from these reviewed sources.

Caveats: No current evidence is provided for cited Evidence rows available after recent evidence window: 0. Mention as competition or IPO context is weaker than direct company event evidence.

269
Argotec
lowweak
Opp 1
Risk 2

Thesis: There is not enough kept recent evidence window evidence in these reviewed sources to form a positive 1 year+ thesis beyond weak historical cohort relevance.

Why now: Why now is weak because the reviewed sources show zero evidence kept within the 90-day recent evidence window for ranking, and the only cited support is an older membership rationale referring to 7 Hawk microsatellites for Italy's IRIDE constellation aboard a SpaceX launch from article: but no article or dated evidence row is provided in the reviewed sources for ranking use.

Caveats: No article is provided for the membership support article: so it cannot be cited as a factual ranked-evidence item under the the evidence standard. Coverage debug shows zero evidence after recent evidence window. Private/public status is not used as a filter and is unclear from these reviewed sources.

270
ArianeGroup
lowweak
Opp 1
Risk 1

Thesis: ArianeGroup appears relevant to launch services in the phase2 rationale, but the reviewed sources provide no direct positive evidence or citable representative summaries for a ranked positive thesis.

Why now: The phase2 rationale references Ariane 6/Arianespace launch context for Amazon Kuiper, but relation/context evidence cannot be used as counterparty propagation and no direct evidence is exposed in the scoring fields. Coverage data shows zero articles after recent evidence window and zero evidence available.

Caveats: Do not use context-only relation logic as direct thesis proof. No direct company-specific event evidence is included here.

271
Arxis, Inc.
lowweak
Opp 1
Risk 1

Thesis: No positive thesis is supported within the retained 90-day evidence window; the reviewed sources only shows older cohort-membership context identifying Arxis as a small satellite manufacturer from article, but no in-window direct positive event or fact is available.

Why now: Why now is unclear because coverage data shows 0 articles after recent evidence window and 0 evidence after recent evidence window, so there is no retained recent catalyst evidence in the reviewed sources.

Caveats: Reviewed evidence cites membership support from, but no representative article is provided, so the underlying claim cannot be restated as direct scored evidence with. Coverage after recent evidence window is empty, limiting conviction.

272
Arxis Inc.
lowweak
Opp 1
Risk 1

Thesis: No positive thesis is supportable from the retained reviewed sources evidence because no direct positive evidence survived the 90-day recent evidence window.

Why now: Why now is weak: the reviewed sources show zero evidence after recent evidence window for Arxis Inc., so there is no current catalyst or current business-state proof in the retained record.

Caveats: Coverage after recent evidence window is empty for this company. Phase-2 membership rationale references support references including: but no article summary or quoted evidence is included in the retained reviewed sources, so it cannot be used for factual claims here.

273
Aselsan
lowweak
Opp 1
Risk 1

Thesis: No retained in-recent evidence window evidence supports a current positive thesis, even though the membership rationale notes LUNA-2 nanosatellite activity.

Why now: The reviewed sources retained zero evidence after the 90-day cutoff, so there is no current catalyst evidence for the 1 year+ ranking despite article-based membership context.

Caveats: Membership rationale cites article, but no article summary or retained evidence row is available here. 24 articles were considered, but none remained after recent evidence filtering.

274
Astranis Space Technologies
lowweak
Opp 1
Risk 1

Thesis: Reviewed evidence rationale references selection under the U.S. Space Force Andromeda program, which could be strategically positive, but no retained evidence are present here to support ranking it higher.

Why now: No retained article or facts remain in the reviewed sources after recent evidence window, so timing and durability cannot be judged from local evidence.

Caveats: Opportunity view depends on uncited membership rationale rather than retained evidence. No recency-confirmed direct evidence in reviewed sources.

275
Astro Digital
lowweak
Opp 1
Risk 1

Thesis: No strong positive thesis is supported. The reviewed sources only says Astro Digital was named as one of Star Catcher's signed power purchase agreement counterparties, implying operation of satellites or space assets, but this is counterparty context from a single article and not sufficient as direct positive evidence (: no provided in reviewed sources).

Why now: No supported current catalyst. The reviewed sources explicitly warns this is counterparty context only, and coverage debug shows no retained evidence after recent evidence window.

Caveats: No current evidence is provided for the cited support article in the reviewed sources. Counterparty context should not be treated as strong propagation evidence. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0.

276
Astrobiome Space
lowweak
Opp 1
Risk 1

Thesis: No positive thesis is supportable from retained evidence in these reviewed sources because no direct positive rows survive the recent evidence window.

Why now: There is no retained evidence showing a current contract milestone, financing event, or product progress inside the recent evidence window.

Caveats: Phase-2 rationale says Astrobiome Space contracted Redwire for a commercial space greenhouse/ISS agriculture mission and cites: and: but no or summaries are available here. Coverage debug shows 6 articles considered and 0 after recent evidence window. Relationship context should not be propagated as stronger evidence without direct retained event/facts.

277
Axiom Space
lowweak
Opp 1
Risk 1

Thesis: No positive thesis is supportable from within the recent evidence window evidence in these reviewed sources. The only cited article is an older external article noting Axiom previously received a NASA commercial space station contract, but it is dated September 2, 2025 and falls outside the reviewed sources' 90-day recent evidence window, so it cannot support a current opportunity call.

Why now: There is no within the recent evidence window catalyst in the available evidence. The only cited context is an older article with September 2, 2025, outside the 90-day evidence window

Caveats: Coverage after recent evidence window is effectively empty: evidence after recent evidence window is 0. Older supporting context exists but was excluded by the 90-day recent evidence window. No direct positive or negative evidence is available.

278
Axiom Space Inc.
lowweak
Opp 1
Risk 1

Thesis: No positive thesis is supportable because the reviewed sources provide no direct positive evidence or citable representative article summaries in the final evidence fields.

Why now: The phase2 rationale says Axiom was mentioned in connection with a lunar suit presentation and an orbital data center feature, but those article details are not surfaced in citable evidence here. Coverage data shows zero articles after recent evidence window and zero available evidence, so there is no current catalyst basis in the reviewed sources.

Caveats: Phase2 rationale is weaker than direct event/fact evidence. No dated current-state evidence is available in the scoring fields.

279
BAE Systems plc
lowweak
Opp 1
Risk 1

Thesis: There may be a space-related opportunity because the membership rationale says BAE Systems was selected by the U.S. Space Force for the Andromeda program, but the reviewed sources does not load the underlying within the recent evidence window evidence or article summaries needed to support a directional thesis.

Why now: Why-now is weak because the reviewed sources show no reviewed evidence after recent evidence window despite many articles considered, leaving no admissible dated evidence in the current output batch.

Caveats: Membership rationale references, and, but no article summaries or evidence are provided here. Coverage debug shows articles after recent evidence window 0 and evidence after recent evidence window 0. Broad-company membership in a cohort is not itself a directional opportunity thesis.

280
Baykar
lowweak
Opp 1
Risk 1

Thesis: No positive thesis is supportable because the retained reviewed sources provide no direct positive evidence for Baykar within the recent evidence window.

Why now: Why now is weak: there are no retained evidence after recent evidence window, and the reviewed sources' membership rationale is based only on weak indirect article context.

Caveats: Phase-2 membership rationale cites and says Fergani Space was described as 'Baykar affiliated,' but no article summary or quote is available in the retained reviewed sources for factual use here. The reviewed sources itself characterizes the evidence as weak, indirect article context.

Risk view

Showing rows 221-240 of 438; 20 rows per page.

Sorted by raw risk score
RankCompanyScoreThesis / Evidence
221
Spacety
lowweak
Opp 2
Risk 2

Thesis: There is no usable in-window article or evidence detail in the reviewed sources to validate the company’s current operating status, financing trajectory, or any adverse development, so the main risk is evidence absence rather than proven business trouble.

Why now: There is no dated evidence retained after recent evidence window for Spacety in these reviewed sources. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window, so recency is uncertain.

Caveats: No representative articles or evidence are provided after recent evidence window. The only support is the phase2 membership rationale, which is weaker than direct event/fact evidence and does not provide /article summaries here. Because there is no in-window evidence, scores remain low on both axes.

222
Spacium
lowweak
Opp 1
Risk 2

Thesis: No direct negative evidence is present; the main issue is stale evidence and resulting uncertainty about current momentum or business state.

Why now: The only cited article is dated January 23, 2025, and the reviewed sources explicitly shows it was dropped by the 90-day recent evidence window cutoff of March 29, 2026.

Caveats: All dated evidence was excluded by recent evidence window. Do not use out-of-window article as current recency proof.

223
SpinLaunch
lowweak
Opp 2
Risk 2

Thesis: Novel launcher and constellation buildout imply execution risk, but these reviewed sources provide no direct negative evidence within the recent evidence window.

Why now: Why-now is weak because the reviewed sources show 0 evidence kept after the 90-day recent evidence window, so recency cannot be established from local evidence.

Caveats: Phase2 membership rationale references and, but no article summaries or direct evidence are included, so they cannot be cited as factual support beyond noting the reviewed sources rationale. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Opportunity score kept low because positive thesis is not directly grounded in usable article evidence in these reviewed sources.

224
SSC Space
lowweak
Opp 2
Risk 2

Thesis: Reviewed evidence risk is mainly lack of evidence visibility rather than documented negative developments. Without available direct evidence, current contract status, capex burden, and follow-on demand are unclear.

Why now: Why now is weak because no evidence survived into the ranking reviewed sources despite the membership rationale.

Caveats: Phase-2 membership rationale references: but no or direct evidence row is available here. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Do not infer opportunity from mission association alone without available evidence.

225
Star Catcher Industries, Inc.
lowweak
Opp 1
Risk 2

Thesis: Risk is mostly uncertainty risk because no kept recent evidence window evidence establish financing, contracts, milestones, or adverse developments.

Why now: Why now is weak because the reviewed sources' membership rationale references article describing an orbital power grid concept, but no article or reviewed evidence are provided for ranking use.

Caveats: No article is available for article. Coverage debug shows zero evidence after recent evidence window. Cannot elevate concept relevance into thesis attractiveness without direct business evidence.

226
Starcloud
lowweak
Opp 4
Risk 2

Thesis: The same rationale suggests category ambiguity and execution risk: orbital AI/data-center activity may be conceptually ambitious, but the reviewed sources does not prove commercialization, deployment, or durable demand. No direct adverse evidence is available, so risk remains moderate and evidence-light rather than event-driven.

Why now: If the fundraising and product positioning are recent, they could support a multi-quarter buildout story, but the reviewed sources explicitly shows zero available evidence after recent evidence window, so recency and sequencing cannot be confirmed.

Caveats: Most supportive facts appear only in membership rationale, not available evidence. Reported funding cannot be treated as fully validated without direct article support in reviewed sources. No, quote, or dated direct summary is available.

227
Stelleo
lowweak
Opp 4
Risk 2

Thesis: Risk remains modest because the reviewed sources offers no adverse evidence, but also no proof of contracts, funding, customer traction, or scaling milestones. That makes the opportunity early-stage and low-conviction.

Why now: The article is within the recent evidence window and dated May 25, 2026, but it is a company-site style description rather than an independently reported business event, so it supports relevance more than momentum

Evidence
  • Article describes Stelleo as a Polish Earth Observation startup that turns satellite data into operational decisions and says it provides protection for infrastructure, harvests, and operations across Europe; May 25, 2026. stelleo.eu

Caveats: Evidence is article-level company context, not a direct commercial milestone. No direct traction, financing, or contract evidence is provided. Same-article repeated rows are not independent confirmation.

228
SWISSto12
lowweak
Opp 3
Risk 2

Thesis: The reviewed sources contain no retained article/evidence detail after recent evidence window to confirm deliveries, customer adoption, financing, or execution setbacks, so business risk cannot be judged confidently.

Why now: There is no dated evidence retained after recent evidence window for SWISSto12. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window, so the timing case is not established from these reviewed sources.

Caveats: Assessment relies only on the reviewed sources' membership rationale, not direct quoted event/fact evidence with support. No representative articles are included despite article IDs being referenced in the rationale. Potential opportunity could be meaningful, but evidentiary support inside these reviewed sources is too thin for a stronger score.

229
Terran Orbital
lowweak
Opp 1
Risk 2

Thesis: Risk scores slightly above minimal only because evidence absence is meaningful for ranking confidence and because the reviewed sources gives no current direct positive operating or contract evidence inside the recent evidence window. There is still no direct adverse event in the reviewed sources.

Why now: There is no valid near-term or long-horizon catalyst from the reviewed sources because coverage data shows zero evidence after recent evidence window; current state cannot be confirmed from local evidence.

Caveats: No evidence remained after the 90-day recent evidence window. The reviewed sources includes only sparse membership rationale, not current direct evidence.

230
The Exploration Company
lowweak
Opp 5
Risk 2

Thesis: Main risk is evidence thinness and uncertain recency: the reviewed sources contain no direct negative evidence, but the only business evidence is undated supporting article context, so current contract status and execution progress are uncertain.

Why now: Why now is weak: the only cited catalyst is an undated article stating the company won an ESA cargo contract, and the reviewed sources provide no newer dated confirmation within the 90-day window. Recency-sensitive conclusions should therefore be cautious.

Evidence
  • The Exploration Company was contracted by the European Space Agency to develop a Low Earth Orbit cargo return service, and the article says it was ranked first and awarded the contract. tech.eu

Caveats: Only undated article-context evidence is present; no direct structured positive event/facts survived. The reviewed sources includes no within the recent evidence window dated follow-up on financing, program execution, or milestone delivery. Article-level context is weaker than direct company event/fact evidence.

231
True Anomaly Centennial
lowweak
Opp 3
Risk 2

Thesis: Risk remains moderate because the reviewed sources provide no direct available evidence after recent evidence window to confirm award economics, schedule, or follow-on conversion.

Why now: Government program selection could matter over 1 year+, but the reviewed sources does not provide surviving evidence with timing details after recent evidence window.

Caveats: No -bearing direct evidence row is available for the referenced Andromeda selection article. Selection does not prove revenue realization or contract scale.

232
Umbra
mediummedium
Opp 5
Risk 2

Thesis: The main risk in these reviewed sources is evidentiary rather than business-specific: there is no direct negative evidence, but also no direct structured positive event row such as a contract, financing, or milestone within the recent evidence window. Opportunity therefore rests on supporting article context rather than stronger company-specific event evidence.

Why now: The most recent dated context is June 22, 2026, which is within the 90-day recent evidence window and indicates Umbra currently operates a SAR constellation and serves government and commercial customers. However, no nearer-term catalyst row is available, so the timing case is moderate rather than strong.

Evidence
  • Published June 22, 2026: Umbra is described as a U.S. commercial space company developing and operating a SAR satellite constellation that delivers rapid, regular, and high-resolution data to public and private customers. eoportal.org

Caveats: Evidence is supporting article context/weak context only, not a direct structured positive event row. The July 31, 2024 Umbra article is outside the 90-day dated recent evidence window and was dropped for recency-sensitive scoring.

233
United Launch Alliance
lowweak
Opp 2
Risk 2

Thesis: No material adverse evidence is available, so there is no supported negative thesis from these reviewed sources alone.

Why now: The membership rationale cites articles: and: but no article summaries or evidence are available after recent evidence filtering for ranking.

Caveats: Launch-industry membership is not itself a directional thesis. Coverage debug shows zero evidence after recent evidence window despite many considered articles. No direct contract, launch cadence, backlog, or failure evidence is available in these reviewed sources.

234
Viasat, Inc.
mediummedium
Opp 4
Risk 2

Thesis: Risk remains moderate because the reviewed sources provide only weak supporting article context rather than direct structured company events, limiting confidence in scope, economics, and timing of impact.

Why now: Recent context exists within the recent evidence window: is dated June 11, 2026 and states Viasat was among operators selected under a combined $437.7 million award and has a defined supplier stack for its PTS-G satellite, which could matter over a 1 year+ horizon. Source date basis is source date.

Evidence
  • Rocket Lab will supply the spacecraft bus for Viasat’s PTS-G satellite, and the article says communications satellite operators SES and Viasat were selected as prime contractors under a combined $437.7 million award to each build and operate a satellite. spacenews.com

Caveats: This is supporting article context only; the reviewed sources classifies it under weak context, so it is weaker than direct event/fact evidence. Same article appears in two weak-context rows and should not be treated as independent confirmation. An older Viasat company-hosted article exists but is outside recent evidence window, February 29, 2024

235
Voyager Technologies Inc.
lowweak
Opp 2
Risk 2

Thesis: A mild risk prior exists only from uncertainty: despite many articles considered, no retained evidence remains after recent evidence window, so no current adverse thesis is established and business-state recency is unclear.

Why now: There is no citable within the recent evidence window evidence in the reviewed sources to justify a strong 1 year+ 'why now' despite broad historical article coverage.

Caveats: Phase-2 rationale references: and: but no or summaries are provided here. Coverage debug shows 78 articles considered but 0 article IDs after recent evidence window and 0 available evidence. Ticker ambiguity exists in aliases (VOYG, VYGR), but the required output ticker is VOYG.

236
VSBLTY Groupe Technologies Corp.
lowweak
Opp 2
Risk 2

Thesis: The same rationale implies adjacency rather than a clearly established core space operator role, creating execution and relevance risk, but no material adverse event evidence is available after recent evidence filtering.

Why now: No reviewed sources-grounded timing support is available for why this matters now over a 1 year+ horizon; the reviewed sources retains zero evidence after the cutoff and provides no citable for article.

Caveats: Reviewed evidence is limited to a membership rationale; there are no representative article summaries, or evidence after recent evidence window. The cited article id is not accompanied by a in the reviewed sources, so it cannot be used for factual claim citation. Slightly higher opportunity/risk than some peers reflects adjacency language in the reviewed sources rationale only, not strong direct evidence.

237
Xdlinx
lowweak
Opp 2
Risk 2

Thesis: No direct negative evidence is present; the practical risk to ranking is simply insufficient current evidence.

Why now: The reviewed sources includes no representative article or retained evidence within the 90-day recent evidence window, so recency and current status are uncertain for Xdlinx in this screen.

Caveats: No retained evidence after recent evidence window. Phase-2 membership support alone is not enough for a stronger score.

238
XDLINX Space Labs
lowweak
Opp 2
Risk 2

Thesis: Risk is modestly elevated versus some peers because the company appears only once in the reviewed sources, and the lack of retained recent evidence means the claimed business standing cannot be validated or updated within the recent evidence window.

Why now: No current catalyst is evidenced; coverage after recent evidence window is empty.

Caveats: Reviewed evidence mentions: but provides no. Higher-revenue claim is only from membership rationale and may not be current. No retained structured positive or negative evidence after recent evidence window.

239
Xona Space
lowweak
Opp 3
Risk 2

Thesis: Risk is mainly execution and proof-of-delivery risk because the surviving evidence is undated company context without dated commercial milestones, customers, or financing in the reviewed sources.

Why now: Why now is weak: the only surviving evidence is undated, so recency-sensitive claims are uncertain

Evidence
  • Company context says Xona Pulsar is low-Earth-orbit positioning, navigation, and timing infrastructure with 258 small satellites; evidence is undated supporting article context. xonaspace.com

Caveats: Evidence is undated and should not be treated as recency proof. No direct positive event or traction evidence is available. Opportunity case is strategic but low-conviction.

240
ADAspace
lowweak
Opp 1
Risk 1

Thesis: No material adverse evidence is available within the reviewed sources' recent evidence window. Risk remains low-scored due to lack of evidence rather than demonstrated safety.

Why now: There is no usable within the recent evidence window evidence in the reviewed sources; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window for ADAspace.

Caveats: Phase-2 membership rationale references article: but the reviewed sources provide no for citation. No direct positive or negative evidence survived the 90-day recent evidence window.